The Company’s orphan drug strategy outlined in November of 2012 is beginning to bear fruit and we intend to pursue orphan diseases aggressively as we see this as the most effective and expeditious route to getting MANF to patients.
When data becomes available in the coming weeks on different applications, we will begin to spend some time reprioritizing our MANF pipeline to ensure that we are maximizing shareholder value
Market Data 
Markets 
AI
